Phase I safety and pharmacokinetic study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in Japanese patients with advanced solid tumors - Danming Zhu; Ni Lu; Takako Eguchi Nakajima; Ting Xu; Haolan Lu; Meng Fu; Pilin Wang; David T.L. Liu; Toshio Shimizu; Walt Cao; Ruiping Dong; Xiaoxiao Wang; et al. (Journal of Clinical Oncology, 2019)